LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in the transformation to digital medicine with an ultrasensitive single molecule testing for the benefit of human health, today announced its expansion into several prominent APAC markets. With this expansion, Quanterix is meeting a huge, unmet demand for the company’s Simoa technology in Japan, China, Singapore, Malaysia, and Thailand, most recently naming Cold Spring Biotech as its official and exclusive distributor in China.
“This is an exciting time for Quanterix and we are thrilled to have found such a strong partner in Cold Spring Biotech to help bring our revolutionary Simoa technology to researchers in China to help fuel more groundbreaking discoveries,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “Some of the world’s leading researchers in China have been asking for Simoa since we launched the technology eighteen months ago and now can harness its power in their own labs to drive innovative research in oncology, neurology, cardiology, inflammation, and other disease areas impacting human health.”
“Cold Spring Biotech (CSB) is extremely pleased to enter into this partnership with Quanterix. We expect to develop and maintain a mutually beneficial relationship with Quanterix and rapidly engage the life science industry in China,” said Pasteur Tai, President of CSB. “China has seen double-digit growth in the biotechnology industry and has become one of the fastest nations in the adoption of new biotechnologies. Simoa is a revolutionary technology which has the world’s most sensitive ELISA immunoassay. We are keen for the opportunity to introduce the technology to the automated ELISA market, providing Chinese researchers with the most advanced technology for their biomarker work.”
With offices in Beijing, Shanghai, Guangzhou, and other cities in China, Cold Spring Biotech Corp. distributes instruments, reagents, and consumables for some the biggest manufacturers in the biotechnology market. In addition to its distribution services, Cold Spring Biotech provides R&D consultation services on research projects and experimental techniques.
Quanterix first executed on its commercial strategy to expand into Asia earlier this year, announcing its entry into Japan, working with their exclusive distributor SCRUM, Inc., of Tokyo. Now, the company has expanded into China markets, naming Cold Spring Biotech as their exclusive distributor, where they already have several orders pending. Quanterix also recently appointed Research Instruments for distribution in Singapore, Thailand and Malaysia and will continue this expansion into Asian markets in 2016.
To learn more about Quanterix and its Simoa technology, please visit: http://quanterix.com/.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com. Investors can access a webcast of Kevin Hrusovsky’s recent JPMorgan presentation at: https://vimeo.com/151844499.